National Consensus Development Panel on Effective Medical Treatment
of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA.1998;280:1936-1943.
Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag Inc; 1991.
Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome
Study (DATOS). Psychol Addict Behav.1997;11:261-278.
Office of National Drug Control Policy. Policy Paper—Opioid Agonist Treatment. Washington, DC: Executive Office of the President, Office of National
Drug Control Policy; March 1999.
Drug Abuse Warning Network Annual Medical Examiner Data 1999. Substance Abuse and Mental Health Services Administration, Office of
Applied Studies Web site. Available at: http://www.samhsa.gov/oas/DAWN/99me_annual.pdf. Accessed August 2, 2001.
Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep.1998;113(suppl):97-106.
Metzger DS, Woody GE, McLellan AT.
et al. Human immunodeficiency virus seroconversion among intravenous drug
users in and out of treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr.1993;6:1049-1056.
Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA.1989;262:1664-1669.
Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA.1995;273:1619-1620.
Guidelines State Methadone Treatment. Vol 1. Rockville, Md: US Dept of Health and Human Services; 1993.
Rettig RA, Yarmolinsky A. Federal Regulation of Methadone Treatment. Washington, DC: Institute of Medicine, National Academy Press; 1995.
O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med.2000;133:40-54.
Senay EC, Barthwell AG, Marks R, Boros P, Gillman D, White G. Medical maintenance: a pilot study. J Addict Dis.1993;12:59-76.
Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. Am J Addict.1999;8:293-299.
Novick DM, Joseph H, Salsitz EA.
et al. Outcomes of treatment of socially rehabilitated methadone maintenance
patients in physicians' offices (medical maintenance): follow-up at three
and a half to nine and a fourth years. J Gen Intern Med.1994;9:127-130.
Novick DM, Pascarelli EF, Joseph H.
et al. Methadone maintenance patients in general medical practice: a preliminary
Salsitz EA, Joseph H, Frank B.
et al. Methadone medical maintenance (MMM): treating chronic opioid dependence
in private medical practice—a summary report (1983-1998). Mt Sinai J Med.2000;67:388-397.
Statistical Power Analysis: A Computer Program [computer
program]. Hillsdale, NJ: Erlbaum Associates; 1988.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum Associates; 1988.
Baumgartner WA, Hill VA. Hair analysis for drugs of abuse. In: Sunshine I, ed. Recent Developments in Therapeutic
Drug Monitoring and Clinical Toxicology. New York, NY: Marcel Dekker
Ware Jr JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36), I: conceptual framework
and item selection. Med Care.1992;30:473-481.
McLellan AT, Kushner H, Metzger D.
et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat.1992;9:199-213.
Zanis DA, McLellan AT, Belding MA, Moyer G. A comparison of three methods of measuring the type and quantity of
services provided during substance abuse treatment. Drug Alcohol Depend.1997;49:25-32.
Radloff LS. The CES-D Scale: a self-report depression scale for research in the
general population. Appl Psychol Measure.1977;1:385-401.
Parrino MW. The tornado of change. J Maintenance Addict.1998;1:71-80.
Greenwood J. Persuading general practitioners to prescribe: good husbandry or a
recipe for chaos? Br J Addiction.1992;87:567-575.
Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners' attitudes toward maintenance drug abuse
treatment with buprenorphine. Addiction.1998;93:1567-1575.
Reese TV. Treating opioid dependence. N Engl J Med.2001;344:530.
Berger VW, Exner DV. Detecting selection bias in randomized clinical trials. Control Clin Trials.1999;20:319-327.
Schulz KF. Subverting randomization in controlled clinical trials. JAMA.1995;274:1456-1458.
Brooner RK, King VL, Kidorf M, Schmidt CWJ. Psychiatric and substance use comorbidity among treatment-seeking opioid
abusers. Arch Gen Psychiatry.1997;54:71-80.
Hartel DM, Schoenbaum EE, Selwyn PA.
et al. Heroin use during methadone maintenance treatment: the importance of
methadone dose and cocaine use. Am J Public Health.1995;85:83-88.
Sees KL, Delucchi KL, Masson C.
et al. Methadone maintenance vs 180-day psychosocially enriched detoxification
for treatment of opioid dependence: a randomized controlled trial. JAMA.2000;283:1303-1310.
Warner EA, Kosten TR, O'Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am.1997;81:909-925.
Carroll KM, Rounsaville BJ, Gordon LT.
et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry.1994;51:177-187.
O'Connor PG, Oliveto AH, Shi JM.
et al. A randomized trial of buprenorphine maintenance for heroin dependence
in a primary care clinic for substance users versus a methadone clinic. Am J Med.1998;105:100-105.
Fiellin DA, Chawarski M, O'Connor PG, Pantalon MV, Schottenfeld RC. Adherence to buprenorphine in office-based treatment of opioid dependence. Drug Alcohol Depend.2001;63(suppl):47.
Lewis DC. Access to narcotic addiction treatment and medical care: prospects
for the expansion of methadone maintenance treatment. J Addict Dis.1999;18:5-20.
Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices:
review of the Scottish experience and implications for US policy. JAMA.2000;283:1343-1348.
Bowden CL, Maddux JF, Esquivel M. Methadone dispensing by community pharmacies. Am J Drug Alcohol Abuse.1976;3:243-254.
Opioid drugs in maintenance and detoxification treatment of opiate
addiction. 66 Federal Register.4076-4102 (2001).